Selected Podcast

Encore Episode: Low Dose Naltrexone for Autoimmune Diseases

Frustrations with diagnosis, treatment and results from conventional Western medicine may prompt you to search for alternatives.

You want an alternative that is safe, effective and well-researched. One excellent resource where you can find research on the effectiveness of supplements is PubMed.

Low dose naltrexone (LDN) is a drug that acts like a nutritional supplement. Initially intended to treat addiction, it is now used to treat autoimmune diseases by arresting their progression.

Doses of 50mg to 100mg block opiod receptors in the brain, preventing patients from experiencing a high when they take drugs. Lower doses of 3mg can have a beneficial immune modulating effect.

It's important to educate yourself about low dose naltrexone before speaking with your doctor about it.

Listen as patient advocate Julia Schopick joins Dr. Holly Lucille to discuss the benefits of low dose naltrexone.

**Email This email address is being protected from spambots. You need JavaScript enabled to view it. for more information about LDN.
Encore Episode: Low Dose Naltrexone for Autoimmune Diseases
Featuring:
Julia Schopick, Author & Patient Advocate
Julia SchopickJulia Schopick is a best-selling author of the book, HONEST MEDICINE: Effective, Time-Tested, Inexpensive Treatments for Life-Threatening Diseases. She is a seasoned radio talk show guest who has appeared on over 100 shows and is often invited back.


Through her writings and her blog, HonestMedicine.com, Julia’s goal is to empower patients to make the best health choices for themselves and their loved ones by teaching them about little-known but promising treatments their doctors may not know about.

Julia’s writings on health and medical topics have been featured in American Medical News (AMA), Alternative & Complementary Therapies, the British Medical Journal and the Chicago Sun-Times.

She coaches authors of world-changing, life-saving books in how to use radio and social media, especially Facebook, to get their messages out to the public. You may reach her via email at This email address is being protected from spambots. You need JavaScript enabled to view it..